Breaking News Instant updates and real-time market news.

AAPL

Apple

$116.05

1.99 (1.74%)

, AA

Alcoa

$28.34

-3.1735 (-10.07%)

12:26
10/11/16
10/11
12:26
10/11/16
12:26

On The Fly: Top stock stories at midday

Stocks opened in negative territory following the worse than expected earnings and revenue reported by Alcoa (AA), which is traditionally seen as the company that "kicks off" earnings season for a given quarter. This earnings season is being highly anticipated and investors were clearly disappointed with the miss. The market picked up downside momentum throughout the morning, with each of the major equity averages down by 1% or more at their worst levels. Oil prices are also down about 1.3%, but remain above $50 per barrel. ECONOMIC NEWS: In the U.S., the NFIB small business optimism index dipped to 94.1 in September, its weakest reading since May. COMPANY NEWS: Shares of Alcoa have dropped about 10% near noon after reporting worse than expected quarterly results, with revenue falling and the company cutting forecasts for its parts businesses. This comes just weeks ahead of Alcoa's plan to separate into two independent publicly traded companies on November 1... Samsung (SSNLF) halted production and distribution of its Galaxy Note 7, asked carriers to stop sales and exchanges of the device, and also asked customers with both original or replacement devices to power down and stop using the phone. Shares of rival smartphone maker Apple (AAPL) advanced almost 1% after the announcement. MAJOR MOVERS: Among the notable gainers was Momenta Pharmaceuticals (MNTA), which advanced almost 12% after Barclays analyst Douglas Tsao upgraded the stock to Overweight. Also higher was YUM! Brands (YUM), which gained about 2% after the company said the separation of its China business will be complete on October 31 and that it expects to return as much as $13.5B to shareholders by 2019 as part of a program started last year. Further, the owner of Pizza Hut, KFC and Taco Bell expects to increase franchise ownership to at least 98% by 2018. Among the noteworthy losers was Rent-A-Center (RCII), which dropped 28% after pre-releasing worse than expected financial information for the third quarter, explaining that system performance issues and outages with its new point-of-sale system resulted in a larger than expected negative impact on Core sales. Peer Aaron's (AAN) is also down more than 11% after Rent-A-Center's announcement. Also lower was Illumina (ILMN), which slid about 25% after the company reported preliminary third quarter results that were worse than expected. Additionally, St. Jude Medical (STJ) dropped about 3% after the medical device maker warned about premature battery depletion of some of its defibrillators, an issue which has been linked to two deaths. INDEXES: Near midday, the Dow was down 165.49, or 0.9%, to 18,163.55, the Nasdaq was down 68.26, or 1.28%, to 5,260.41, and the S&P 500 was down 21.92, or 1.01%, to 2,141.74.

AAPL

Apple

$116.05

1.99 (1.74%)

AA

Alcoa

$28.34

-3.1735 (-10.07%)

SSNLF

Samsung

MNTA

Momenta

$11.77

0.17 (1.47%)

YUM

Yum! Brands

$88.65

1.2603 (1.44%)

RCII

Rent-A-Center

$12.88

0.16 (1.26%)

AAN

Aaron's

$22.79

-2.83 (-11.05%)

ILMN

Illumina

$184.85

0.36 (0.20%)

STJ

St. Jude Medical

$78.51

-2.77 (-3.41%)

  • 11

    Oct

  • 11

    Oct

  • 13

    Oct

  • 14

    Oct

  • 19

    Oct

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 01

    Nov

  • 06

    Nov

  • 14

    Nov

  • 13

    Mar

AAPL Apple
$116.05

1.99 (1.74%)

10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Apple has positive read through from Dialog results, says RBC Capital
After Dialog issued a positive preannouncement due to higher than expected Mobile Services revenue, RBC Capital analyst Amit Daryanani thinks that the Dialog results should comfort Apple investors heading into that company's September quarter results. The analyst notes that Apple accounts for 75%-80% of Dialog's revenue. He keeps a $125 price target and Outperform rating on Apple.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Apple average selling prices could beat expectations, says RBC Capital
RBC Capital analyst Amit Daryanani says that his analysis indicates that the average selling prices of Apple's iPhone 7 could significantly exceed Street expectations. Stronger demand for the "plus" model versus the last two years, along with the fact that Apple is charging a $120 premium for the "plus" model versus a $100 premium historically, should boost average selling prices, the analyst stated. He thinks that Apple's September quarter revenue could beat expectations by a "modest" amount, while the company's December quarter guidance could be "materially ahead of Street expectations." He keeps a $125 price target and Outperform rating on the stock.
10/10/16
DBAB
10/10/16
INITIATION
Target $90
DBAB
Sell
Deutsche sees Netflix takeover as unlikely, starts shares at Sell
Deutsche Bank analyst Bryan Kraft initiated shares of Netflix (NFLX) with a Sell rating and $90 price target. The stock closed Friday down 25c to $104.82. The risk/reward is unattractive as consensus expectations reflect an "optimistic case," Kraft tells investors in a research note. Market expectations appear too high through 2020, the analyst contends. He also expresses skepticism that Netflix will be acquired. The business is "too fully formed" and valued to be acquired by Disney (DIS) and Apple (AAPL), Kraft writes. He also sees Amazon.com (AMZN) as a competitive risk to Netflix.
10/11/16
DRXL
10/11/16
NO CHANGE
Target $185
DRXL
Buy
Apple could gain 8M iPhone units from Note 7 troubles, says Drexel Hamilton
Drexel Hamilton analyst Brian White estimates Apple (AAPL) has an opportunity to pick up "at least" 8 million incremental iPhone units in calendar year 2016 due to the Galaxy Note 7 being scrapped, noting that original market expectations were for Samsung (SSNLF) to ship about 10M-14M Galaxy Note 7 units in the second half of this year. The "fiasco" could permanently damage Samsung's smartphone brand, resulting in Apple market share gains, White added. The analyst keeps a Buy rating and $185 price target on Apple shares.
AA Alcoa
$28.34

-3.1735 (-10.07%)

09/09/16
09/09/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Express (AXP) initiated with an Underweight at Atlantic Equities. 2. Alcoa (AA) initiated with a Neutral at Seaport Global. 3. Blue Buffalo Pet Products (BUFF) initiated with an Outperform at Oppenheimer. 4. Harley-Davidson (HOG) initiated with an Outperform at Bernstein. 5. Verifone (PAY) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
GHSC
09/09/16
INITIATION
Target $11
GHSC
Neutral
Alcoa initiated with a Neutral at Seaport Global
Seaport Global analyst Josh Sullivan initiated Alcoa with a Neutral and $11 price target.
05/23/16
05/23/16
UPGRADE
Target $11

Buy
Alcoa upgraded to Buy from Neutral at BofA/Merrill
As previously reported, BofA/Merrill upgraded Alcoa to Buy from Neutral and raised its price target to $11 from $10.50. Analyst Timna Tanners said aluminum and alumina has become a lesser portion of Alcoa's earnings yet shares have become increasingly correlated to aluminum pricing while aerospace exposure now leaves it with an estimated 75% of its earnings levered to the segment. Tanners is confident in an upswing in aero-heavy downstream results and sees engine deliveries up 10% in 2016 and 18% in 2017. The analyst views the recent pullback in Alcoa shares as a buying opportunity given reduced commodity exposure and increased aero contribution.
SSNLF Samsung

08/01/16
NEED
08/01/16
NO CHANGE
Target $65
NEED
Buy
Synaptics price target lowered to $65 from $88 at Needham
Needham analyst Rajvindra Gill lowered his price target for Synaptics (SYNA) to $65 from $88 on a lower earnings multiple as he remains uncertain on whether the company has secured the OLED DDIC for Apple's (AAPL) iPhone 8 versus an internal Samsung (SSNLF) solution. The analyst reiterates a Buy rating on Synaptics' shares, saying the company will remain one of the leaders in the display markets.
06/23/16
BFIN
06/23/16
NO CHANGE
BFIN
Fitbit faces 'fight of its life,' GoPro Karma delay a problem, says BlueFin
In an update on the wearable space, BlueFin analysts John Donovan and Steve Mullane make the case that Fitbit (FIT) is "in for the fight of its life" given mounting competition that is coming from Samsung (SSNLF), Apple (AAPL), Garmin (GRMN) and Under Armour (UA), adding that the sizable inventory of Alta and Blaze devices that it must deplete in this competitive environment puts Fitbit is in a "precarious position." The analyst add that Apple's watchOS improvements "further paint Fitbit into a corner," but noted that market data suggests consumers are looking for wearables under $200, which is in the "sweet spot" of Fitbit's portfolio. Weighing in on GoPro (GPRO), the analysts wonder if the Hero5 will be compelling enough to make consumers buy another camera and note that its upcoming Karma drone is very late to market and "facing daunting odds."
04/26/16
NEED
04/26/16
NO CHANGE
NEED
Apple supply chain names to rebound, says Needham
Needham analyst Rajvindra Gill expects a rebound in the Apple (AAPL) supply chain names given its underperformance over the last 25 days and the relatively good quarterly results from Knowles (KN). Among the names, the analyst sees Cirrus Logic (CRUS) increasing its dollar content per unit about 40% for the iPhone 7 cycle, with possible upside of 80%-100% for the iPhone 7S in 2017 with the inclusion of adaptive noise cancellation. Knowles, which generated 25% of sales from Apple and less than 10% of sales from Samsung (SSNLF), posted better-than-expected results and guidance, the analyst tells investors in a research note.
MNTA Momenta
$11.77

0.17 (1.47%)

09/07/16
MAXM
09/07/16
DOWNGRADE
MAXM
Sell
Momenta downgraded to Sell from Hold at Maxim
08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
YUM Yum! Brands
$88.65

1.2603 (1.44%)

09/29/16
OPCO
09/29/16
NO CHANGE
Target $97
OPCO
Outperform
Yum! Brands remains a favorite at Oppenheimer
Oppenheimer analyst Brian Bittner says Yum! Brands remains one of his "favorite Outperforms," despite its 23% year-to-date gain. The analyst raised his price target on the stock to $97 from $96, citing his updated sum-of-parts heading into the October 31 separation of the company's China business. Nonetheless, Bittner notes that this does not incorporate additional potential upside from an attractive G&A opportunity, potential for larger than expected capital returns post-separation at both entities, and continued earnings power restoration at Yum China. He reiterates an Outperform rating on the shares.
09/23/16
09/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from Sector Perform by RBC analyst Mark Mahaney, who cut his price target to $14 from $17. The research firm's survey of more than 1,100 advertising professionals and their attitudes towards Facebook (FB), Google (GOOG), Twitter and other high-profile names showed that, despite marketing budgets continuing to shift online, interest in the microblog platform appears to be declining. Of note, Twitter shares have surged this morning after CNBC's David Faber reported that Twitter is moving closer to selling itself and has received expressions of interest in a possible sale, although no deal is imminent. 2. Yum! Brands (YUM) downgraded to Outperform from Top Pick by RBC Capital analyst David Palmer based on valuation. His price target on Yum shares remains $97. 3. Becton Dickinson (BDX) downgraded to Sell from Neutral by Citi analyst Amit Hazan, who thinks a cyclical U.S. slowdown will push the company's organic growth below expectations. The analyst, who also sees a diminishing impact on Becton's growth from emerging markets, cut his price target for the shares to $165 from $167. 4. NextEra Energy (NEE) downgraded to Hold from Buy by Deutsche Bank analyst Jonathan Arnold, as he sees limited near-term upside with the shares up 23% year-to-date. "Extraordinarily frosty commentary" from two of three PUCT commissioners yesterday regarding NextEra's Oncor deal indicates an uphill battle in getting it approved, Arnold tells investors. 5. AVANGRID (AGR) downgraded to Underweight from Neutral by JPMorgan analyst Christopher Turnure, who thinks both the company's growth guidance and consensus expectations "appear ambitious." He lowered his price target for the shares to $41 and $44 and notes he does not have confidence in AVANGRID's near-term growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
BERN
09/29/16
NO CHANGE
BERN
New Yum! poised to benefit from cost cutting, unit growth, says Bernstein
Bernstein analyst Sara Senatore says that New Yum! - the global franchisor of KFC, Pizza Hut, and Taco Bell which will trade separately from the current company's China assets following an upcoming spin off - should benefit from cost cutting and steady unit growth. New Yum! will be able to cut up to $140M+.of costs, and "steady unit growth" should "provide underlying support" for its revenue, she stated. The analyst keeps a $98 price target and Outperform rating on current, combined Yum!.
10/06/16
OPCO
10/06/16
NO CHANGE
Target $97
OPCO
Outperform
Oppenheimer would be aggressive buyer of Yum! Brands below $90
After Yum! Brands reported an in-line earnings quarter, Oppenheimer analyst Brian Bittner remains attracted to the shares ahead of several catalysts. The analyst would be an aggressive buyer of Yum! Brands below $90 per share. He reiterates an Outperform rating and $97 price target on the stock.
RCII Rent-A-Center
$12.88

0.16 (1.26%)

01/12/16
01/12/16
DOWNGRADE

Hold
Rent-A-Center downgraded on rent to own trends at BB&T
As noted earlier, BB&T downgraded Rent-A-Center to Hold from Buy. The firm says that the company is being hurt by the transition of rent-to-own business from brick and mortar to virtual. The firm thinks the company may have to cut its dividend.
01/12/16
01/12/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Apple (AAPL) downgraded to Negative from Mixed at OTR Global... Asbury Automotive (ABG) downgraded to Hold from Buy at Craig-Hallum... AvalonBay (AVB) downgraded to Market Perform from Outperform at Cowen... BHP Billiton (BHP) downgraded to Underweight from Equal Weight at Barclays... Canadian Natural (CNQ) downgraded to Equal Weight from Overweight at Morgan Stanley... Cloud Peak (CLD) downgraded to Underweight from Equal Weight at Barclays... Comerica (CMA) downgraded to Underperform from Buy at BofA/Merrill... Concho Resources (CXO) downgraded to Hold from Buy at Jefferies... DDR Corp. (DDR) downgraded to Hold from Buy at Jefferies... DHT Holdings (DHT) downgraded to Neutral from Overweight at JPMorgan... Diageo (DEO) downgraded to Hold from Buy at Stifel... E-Trade (ETFC) downgraded to Buy from Conviction Buy at Goldman... EQT Corporation (EQT) downgraded to Hold from Buy at Jefferies... Encana (ECA) downgraded to Equal Weight from Overweight at Morgan Stanley... Essex Property Trust (ESS) downgraded to Market Perform from Outperform at Cowen... Euronav NV (EURN) downgraded to Neutral from Overweight at JPMorgan... F5 Networks (FFIV) downgraded to Hold from Buy at Deutsche Bank... Freeport McMoRan (FCX) downgraded to Hold from Buy at Jefferies... Great Plains Energy (GXP) downgraded to Neutral from Buy at BofA/Merrill... HCP (HCP) downgraded to Underperform from Hold at Jefferies... HeartWare (HTWR) downgraded to Neutral from Overweight at JPMorgan... InterContinental (IHG) downgraded to Neutral from Buy at Citi... Interactive Brokers (IBKR) downgraded to Sell from Neutral at Goldman... KNOT Offshore Partners (KNOP) downgraded to Neutral from Buy at Citi... LPL Financial (LPLA) downgraded to Sell from Neutral at Citi... Laclede (LG) downgraded to Underweight from Equal Weight at Morgan Stanley... Lazard (LAZ) downgraded to Neutral from Buy at Goldman... Liberty Property (LPT) downgraded to Market Perform from Outperform at Cowen... Marathon Oil (MRO) downgraded to Equal Weight from Overweight at Morgan Stanley... McKesson (MCK) downgraded to Market Perform from Outperform at Raymond James... Mead Johnson (MJN) downgraded to Neutral from Buy at Nomura... Medical Properties Trust (MPW) downgraded to Hold from Buy at Jefferies... NGL Energy Partners (NGL) downgraded to Hold from Buy at Stifel... Occidental Petroleum (OXY) downgraded to Hold from Buy at Jefferies... Omega Healthcare (OHI) downgraded to Hold from Buy at Jefferies... Patterson-UTI (PTEN) downgraded to Neutral from Overweight at Simmons... Peabody (BTU) downgraded to Underperform from Hold at Jefferies... Penn National (PENN) downgraded to Neutral at BofA/Merrill... Pinnacle West (PNW) downgraded to Underweight from Equal Weight at Morgan Stanley... Pioneer Energy (PES) downgraded to Neutral from Overweight at Simmons... Progressive Waste (BIN) downgraded to In-Line from Outperform at Imperial Capital... Prosperity Bancshares (PB) downgraded to Underperform from Neutral at BofA/Merrill... Raymond James (RJF) downgraded to Neutral from Buy at Citi... Rent-A-Center (RCII) downgraded to Hold from Buy at BB&T... Roadrunner (RRTS) downgraded to Peer Perform from Outperform at Wolfe Research... Rose Rock Midstream (RRMS) downgraded to Equalweight from Overweight at Capital One... Rouse Properties (RSE) downgraded to Underperform from Neutral at BofA/Merrill... SABMiller (SBMRY) downgraded to Hold from Buy at Stifel ... Scientific Games (SGMS) downgraded to Underperform from Neutral at BofA/Merrill... Southern Copper (SCCO) downgraded to Equal Weight from Overweight at Barclays... Synergy Resources (SYRG) downgraded to Equal Weight from Overweight at Stephens... Taubman Centers (TCO) downgraded to Underperform from Hold at Jefferies... Teekay Tankers (TNK) downgraded to Underweight from Overweight at JPMorgan... Telenor (TELNY) downgraded to Underweight from Overweight at JPMorgan... UDR, Inc. (UDR) downgraded to Market Perform from Outperform at Cowen... Vedanta Resources (VDNRF) downgraded to Underperform from Hold at Jefferies... Western Gas Partners (WES) downgraded to Neutral from Buy at BofA/Merrill... Whiting Petroleum (WLL) downgraded to Underweight from Equal Weight at Morgan Stanley... Zurich Insurance (ZURVY) downgraded to Underweight from Neutral at JPMorgan.
03/15/16
RAJA
03/15/16
UPGRADE
Target $21
RAJA
Strong Buy
Rent-A-Center upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Budd Bugatch upgraded Rent-A-Center to Strong Buy and raised his price target to $21 from $18. The analyst has increased conviction that forward estimates will prove to be too low given initiatives to improve the middle of the company's consolidated P&L, a strengthening balance sheet and deleveraging, and favorable risk/reward.
05/23/16
05/23/16
INITIATION
Target $27

Buy
Rent-A-Center initiated with a Buy at Topeka
Target $27.
AAN Aaron's
$22.79

-2.83 (-11.05%)

03/23/16
NRCS
03/23/16
NO CHANGE
Target $35
NRCS
Buy
Aaron's shares appear 'dramatically' undervalued, says Northcoast
Northcoast analyst Nick Mitchell said Aaron's Inc shares seem "dramatically" undervalued. The analyst continues to believe Progressive is the market leader in the kiosk channel with an addressable market of $25B and estimates that only $3.5B or less of the potential opportunity is currently being captured. Mitchell sees a long runway for growth remaining and estimates Progressive has the ability to sustainably generate incremental operating margins in the range of 14.0% to 20.0%. The analyst rates Aaron's a Buy with a $35 price target on shares.
03/29/16
STFL
03/29/16
NO CHANGE
STFL
Aaron's weakness has created attractive entry point, says Stifel
Noting that Aaron's stock has declined to $24.50 from the upper $30s price it reached in 4Q15, Stifel says it's only reduced its earnings estimates for the company by 6%-7% during that time. The firm remains confident about the outlook for the company's Progressive unit, as it predicts that the unit's growth will accelerate this year and in 2017. Stifel keeps a $32.50 price target and Buy rating on the shares.
04/13/16
SIDC
04/13/16
INITIATION
Target $33
SIDC
Buy
Aaron's re-initiated with a Buy at Sidoti
Target $33.
05/23/16
05/23/16
INITIATION
Target $30

Buy
Aaron's initiated with a Buy at Topeka
Target $30.
ILMN Illumina
$184.85

0.36 (0.20%)

10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
10/11/16
SBSH
10/11/16
DOWNGRADE
Target $140
SBSH
Neutral
Illumina downgraded to Neutral from Buy at Citi
Citi analyst Daniel Arias downgraded Illumina to Neutral saying last night's preannouncement marked the company's fourth miss in six quarters. "Forecasting capabilities have clearly diminished," Arias tells investors in a research note. He lowered his price target for the shares to $140 and thinks the stock could hit the $110-$120 range today. Illumina is trading down $48.59, or 26%, to $136.26 in the pre-market.
10/11/16
PIPR
10/11/16
NO CHANGE
Target $150
PIPR
Overweight
Illumina selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst William Quirk recommends using today's selloff in shares of Illumina as a buying opportunity. The stock traded down 24% last night after the company reported preliminary Q3 revenue of $607M, below the Street's $628.3M estimate. A lower number of HiSeq 2500/4000 installs as well as a HiSeq X Ten placement slip drove the revenue miss, Quirk tells investors in a research note. He notes, however, that his HiSeq X checks found the pipeline remains "very strong" at 95 systems, with a majority driven by the Chinese precision medicine program. He views $130 as a "technical floor" for the shares and dropped his price target for Illumina to $150 from $163. Quirk keeps an Overweight rating on the name.
10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
STJ St. Jude Medical
$78.51

-2.77 (-3.41%)

09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.

TODAY'S FREE FLY STORIES

BMRN

BioMarin

$82.45

0.24 (0.29%)

, ESALY

Eisai

$57.37

-0.545 (-0.94%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.45

0.24 (0.29%)

ESALY

Eisai

$57.37

-0.545 (-0.94%)

GWPH

GW Pharmaceuticals

$117.45

5.13 (4.57%)

IART

Integra LifeSciences

$76.78

1 (1.32%)

MDT

Medtronic

$71.67

-0.34 (-0.47%)

MNK

Mallinckrodt

$53.56

-0.05 (-0.09%)

NVTA

Invitae

$7.05

0.1 (1.44%)

SAGE

SAGE Therapeutics

$51.82

2.8 (5.71%)

WTKWY

Wolters Kluwer

$35.23

1.15 (3.37%)

ZGNX

Zogenix

$12.70

-0.35 (-2.68%)

ZYNE

Zynerba

$13.18

-0.46 (-3.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

04:55
12/06/16
12/06
04:55
12/06/16
04:55
General news
Productivity and Costs Unit labor costs to be reported at 08:30 »

Productivity and Costs…

ADSK

Autodesk

$71.18

0.61 (0.86%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

GWB

Great Western

$40.42

0.99 (2.51%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Great Western management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

ECL

Ecolab

$118.56

1.67 (1.43%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 12

    Dec

CGNX

Cognex

$58.03

0.03 (0.05%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Cognex management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SMCI

Super Micro Computer

$27.60

0.6 (2.22%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Super Micro Computer management to meet with Maxim »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Feb

  • 09

    Feb

LLL

L-3 Communications

$158.46

1.23 (0.78%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
L-3 Communications to host investor meeting with conference call hookup »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

CSV

Carriage Services

$27.79

0.29 (1.05%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Carriage Services management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

04:55
12/06/16
12/06
04:55
12/06/16
04:55
General news
Productivity and Costs Nonfarm productivity to be reported at 08:30 »

Productivity and Costs…

EKSO

Ekso Bionics

$4.67

0.4 (9.37%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
American College of Neuropsychopharmacology to hold an annual meeting »

55th Annual Meeting of…

TWOU

2U

$32.15

0.99 (3.18%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
2U management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

04:55
12/06/16
12/06
04:55
12/06/16
04:55
General news
Factory Orders to be reported at 10:00 »

October Factory Orders…

RGLS

Regulus

$2.85

0.35 (14.00%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

AGO

Assured Guaranty

$36.95

0.4 (1.09%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Assured Guaranty management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CHEF

Chefs' Warehouse

$14.10

0.9 (6.82%)

, SFS

Smart & Final Stores

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Barclays to hold a conference »

2016 Eat, Sleep, Play:…

CHEF

Chefs' Warehouse

$14.10

0.9 (6.82%)

SFS

Smart & Final Stores

SAFM

Sanderson Farms

$85.90

3.94 (4.81%)

JACK

Jack in the Box

$108.24

1.09 (1.02%)

CAKE

Cheesecake Factory

$61.40

0.92 (1.52%)

KR

Kroger

$32.93

-0.37 (-1.11%)

YUM

Yum! Brands

$63.06

0.64 (1.03%)

SYY

Sysco

$53.48

-0.11 (-0.21%)

RLJ

RLJ Lodging Trust

$23.38

0.86 (3.82%)

RCL

Royal Caribbean

$81.05

1.49 (1.87%)

PENN

Penn National

$13.50

0.13 (0.97%)

MGM

MGM Resorts

$28.97

-0.04 (-0.14%)

MAR

Marriott

$81.00

1.8 (2.27%)

LVS

Las Vegas Sands

$61.12

0.13 (0.21%)

HT

Hersha Hospitality

$20.75

0.19 (0.92%)

EAT

Brinker

$53.43

0.15 (0.28%)

DPZ

Domino's Pizza

$166.29

-1.71 (-1.02%)

CMG

Chipotle

$396.27

-3.76 (-0.94%)

CHH

Choice Hotels

$52.75

0.85 (1.64%)

BOJA

Bojangles

$18.75

0.65 (3.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 07

    Dec

  • 13

    Dec

  • 15

    Dec

  • 09

    Jan

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
KeyBanc to hold a conference »

Consumer Conference is…

ON

ON Semiconductor

$11.23

0.11 (0.99%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
ON Semiconductor management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ECOM

ChannelAdvisor

$14.30

0.25 (1.78%)

, BCOV

Brightcove

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Raymond James to hold a conference »

Technology Investors…

ECOM

ChannelAdvisor

$14.30

0.25 (1.78%)

BCOV

Brightcove

EXTR

Extreme Networks

$4.43

0.15 (3.50%)

CTRL

Control4

$11.19

0.07 (0.63%)

JNPR

Juniper

$26.93

0.1 (0.37%)

SNX

SYNNEX

$121.70

2.97 (2.50%)

GIG

GigPeak

$2.62

0.15 (6.07%)

QRVO

Qorvo

$52.48

1.94 (3.84%)

FLEX

Flex

$14.55

0.17 (1.18%)

WK

Workiva

BNFT

Benefitfocus

$28.20

1.1 (4.06%)

HAR

Harman

$109.66

0.19 (0.17%)

FIT

Fitbit

$8.03

-0.11 (-1.35%)

ULTI

Ultimate Software

$192.96

1.56 (0.82%)

CRTO

Criteo

$39.33

0.65 (1.68%)

MSCC

Microsemi

$53.40

0.45 (0.85%)

VC

Visteon

$79.86

0.05 (0.06%)

ADI

Analog Devices

$70.60

0.49 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 13

    Dec

  • 14

    Dec

  • 05

    Jan

  • 10

    Jan

  • 14

    Feb

APTS

Preferred Apartment

$13.48

0.07 (0.52%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Preferred Apartment management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PLNT

Planet Fitness

$20.17

0.15 (0.75%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Planet Fitness management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Jan

SUM

Summit Materials

$23.53

0.27 (1.16%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Summit Materials management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 19

    Dec

CSIQ

Canadian Solar

$11.79

0.72 (6.50%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
Canadian Solar management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Dec

CEVA

CEVA

$30.75

0.9 (3.02%)

04:55
12/06/16
12/06
04:55
12/06/16
04:55
Conference/Events
CEVA management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.